A2-Binding peptide

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 598133

CAS#: 119425-35-3

Description: A2-Binding peptide has a substitution of lysine at position 62 of MP 57-68, K62, KGILGKVFTLTV; from influenza A matrix protein, involved in assembly of MHC Class I molecules.

Chemical Structure

img
A2-Binding peptide
CAS# 119425-35-3
Instruction

Theoretical Analysis

MedKoo Cat#: 598133
Name: A2-Binding peptide
CAS#: 119425-35-3
Chemical Formula: C61H106N14O15
Exact Mass: 1,274.80
Molecular Weight: 1,275.600
Elemental Analysis: C, 57.44; H, 8.38; N, 15.37; O, 18.81

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: A2-Binding peptide;

IUPAC/Chemical Name: L-lysylglycyl-L-isoleucyl-L-leucylglycyl-L-lysyl-L-valyl-L-phenylalanyl-L-threonyl-D-leucyl-L-threonyl-L-valine

InChi Key: NBOKFONQQZRHRY-DINGYSCKSA-N

InChi Code: InChI=1S/C61H106N14O15/c1-13-36(10)49(71-46(79)31-65-52(80)40(64)23-17-19-25-62)58(86)68-42(27-32(2)3)53(81)66-30-45(78)67-41(24-18-20-26-63)54(82)72-47(34(6)7)57(85)70-44(29-39-21-15-14-16-22-39)56(84)74-50(37(11)76)59(87)69-43(28-33(4)5)55(83)75-51(38(12)77)60(88)73-48(35(8)9)61(89)90/h14-16,21-22,32-38,40-44,47-51,76-77H,13,17-20,23-31,62-64H2,1-12H3,(H,65,80)(H,66,81)(H,67,78)(H,68,86)(H,69,87)(H,70,85)(H,71,79)(H,72,82)(H,73,88)(H,74,84)(H,75,83)(H,89,90)/t36-,37+,38+,40-,41-,42-,43+,44-,47-,48-,49-,50-,51-/m0/s1

SMILES Code: CC(C)[C@@H](C(O)=O)NC([C@H]([C@H](O)C)NC([C@@H](CC(C)C)NC([C@H]([C@H](O)C)NC([C@@H](NC([C@@H](NC([C@H](CCCCN)NC(CNC([C@@H](NC([C@H]([C@@H](C)CC)NC(CNC([C@H](CCCCN)N)=O)=O)=O)CC(C)C)=O)=O)=O)C(C)C)=O)Cc1ccccc1)=O)=O)=O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 1,275.60 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Wang P, Vánky F, Végh Z, Persson U, Hising C, Klein E. Assembly of MHC class I molecules in ex vivo carcinoma cells induced by IFN-gamma or by a binding peptide. Cell Immunol. 1992 Jul;142(2):296-302. PubMed PMID: 1623553.

2: Kanaoka S, Yamasaki S, Okino T, Inoue N, Shimada Y, Kaneko M, Otaka A, Fujii N, Imamura M. Induction of human leukocyte antigen (HLA)-A2-restricted and MAGE-3-gene-derived peptide-specific cytolytic T lymphocytes using cultured dendritic cells from an HLA-A2 esophageal cancer patient. J Surg Oncol. 1999 May;71(1):16-21. PubMed PMID: 10362086.

3: Tung CW, Ziehm M, Kämper A, Kohlbacher O, Ho SY. POPISK: T-cell reactivity prediction using support vector machines and string kernels. BMC Bioinformatics. 2011 Nov 15;12:446. doi: 10.1186/1471-2105-12-446. PubMed PMID: 22085524; PubMed Central PMCID: PMC3228774.

4: Schuler-Thurner B, Dieckmann D, Keikavoussi P, Bender A, Maczek C, Jonuleit H, Röder C, Haendle I, Leisgang W, Dunbar R, Cerundolo V, von Den Driesch P, Knop J, Bröcker EB, Enk A, Kämpgen E, Schuler G. Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1+ melanoma patients by mature monocyte-derived dendritic cells. J Immunol. 2000 Sep 15;165(6):3492-6. PubMed PMID: 10975870.

5: Barrett J, Guimaraes A, Cullis J, Goldman JM. Immunological characterization of the tumor-specific bcr/abl junction of Philadelphia chromosome positive chronic myeloid leukemia. Stem Cells. 1993 Oct;11 Suppl 3:104-8. PubMed PMID: 8298471.